By rapidly de-risking novel science and enriching partner pipelines with best-in-class molecules, i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year time framework. i2020's vast scientific and global resource network tailored specifically to the needs of early drug development programs allows it to take on projects in a wide array of therapeutic areas, from immunology to infectious diseases and beyond. By successfully leveraging agile development principles and flexible partnering business models, i2020 plans to co-create 15 diverse drug discovery programs in 2018.
i2020 Fact check
Partners & Collaborators in 15 countries around the globe.
i2020 offers its members the access to a wide global resource network tailored specifically to the needs of early drug development programs: venture partners experienced in early stage investments, a management team seasoned in team of early drug development management experts, and a growing execution network of pre-qualified CROs with group rates for supplies and services.
agile science programming taps into a wide spectrum of therapeutic areas.
By deploying a robust network of R&D, business strategy and scientific resources, i2020 is able to co-create 15 diverse discovery programs in 2018, tapping into external innovation of VC, industrial and academic partners. The use of agile programming principles allows i2020 to take on projects in a wide array of therapeutic areas, from immunology to oncology and beyond.
drug development heavy lifting done with flexible partnering business models.
Entrepreneurial activities are project-based and tailored to each program, supported by the initial funding of US$30 million from the specialty life science investor, Torrey Pines Investment. Each program is eligible for up to US$2 million depending on the partnering and shared investments potential. Partnering business model could span a solution from equity investment, a non equity participation, and an option-based pre-commercial partnering.
how does i2020 work?
From early drug discovery to advanced lead and clinical candidate.
i2020 is looking for research programs with differentiated biology and established development paradigms to contribute to and advance to the Target Product Profile.
I2020 in the news
learn more about i2020, our latest news, partners, collaborators and members
i2020 Accelerator Invests in Developing Novel Highly-Specific Approaches to Treatment of Neurodegenerative Diseases Based on Previously Unrecognized Protein-Protein Interactions
i2020 Accelerator announced today its plans to invest in a cutting-edge research program based out of the University of Turku (UTU), Finland. The program studies previously unrecognized protein-protein interactions that disrupt The N-methyl-D-aspartate receptor (NMDA) signaling pathways, the hyperactivity of which plays a pivotal role in many neuro-degenerative conditions and neuropathic pain.
Meet i2020 at the LSX Nordic Congress on 28-29 August 2019
We are happy to announce that our Business Development Director, Simon Bennett, will be representing us at the LSX Nordic Congress this year. The LSX is a senior executive conference and partnering event which gives life science companies the resources they need to manage investment, business planning and partnering opportunities more effectively. We are excited to share our own life science expertise and that of our vast global network of partners at this event, and will be happy to see you there on August 28-29!
Snap Bio and i2020 Accelerator (Torrey Pines Investment) Reach Lead Compounds Milestone for Pediatric Oncology and Advanced Liver Cancer Programs
Snap Bio, Inc. and Torrey Pines Investment (TPI) announced today that their joint early drug discovery program within the framework of the i2020 Accelerator has resulted in achieving the projected milestone in developing several small molecule lead candidates for treatment of Hepatocellular carcinoma (HCC) and Hepatoblastoma. The milestone is marked with an outstanding selectivity profile and promising overall animal data in rodents for the lead candidates.
Torrey Pines Investment's i2020 Accelerator to Advance Snap Bio's Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases
Torrey Pines Investment announced today that Snap Bio, Inc. has joined its early drug discovery ecosystem through its i2020 Accelerator specialty investment framework, which includes a three-way partnership with ChemDiv, Inc. Under the terms of the agreement, Snap Bio will leverage ChemDiv's unique integrated discovery platform, while Torrey Pines Investment will deploy its financial and BD&L capabilities to help Snap Bio advance their highly potent and selective kinase inhibitors for treating endodermal cancers and autoimmune diseases.
Torrey Pines Launches i2020 Accelerator for Early Therapeutics
SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- Torrey Pines Investment announced today the launch and initial funding of its i2020 Accelerator initiative. With Torrey Pines funding of up to US$30 million, i2020 implements agile development principles to accelerate small molecules with clearly established development paradigms and paths towards clear differentiation and competitive edge as advanced leads and clinical candidates.